Find drug development pipeline and deal Updates information

Lead Product(s): THR-687

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 05, 2020

Details:

THR-687 is expected to enter a Phase 2 clinical trial in H2 2020. Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020.